Rhythm PharmaceuticalsNASDAQ: RYTM

- European Commission decision anticipated in the second half of 2024 - BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorization for IMCIVREE® (setmelanotide) include children between 2 and younger than 6 years old with obesity due to Bardet Biedl syndrome (BBS) or pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency. “We continue to work closely with health authorities throughout the European Union to make IMCIVREE available to eligible patients with uncontrolled hunger and early-onset, severe obesity associated with these rare neuroendocrine diseases,” said Yann Mazabraud, Executive Vice President, Head of International at Rhythm Pharmaceuticals.

BOSTON, June 11, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that on June 6, 2024, the Compensation & Management Development Committee of Rhythm's Board of Directors granted inducement equity grants covering an aggregate of 56,080 shares of its common stock to ten new employees, consisting of inducement stock options to purchase an aggregate of 9,230 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 46,850 shares of its common stock.

BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 9:20 a.m.

Rhythm Pharmaceuticals (RYTM) lacks the necessary combination of key elements for a potential earnings beat in its upcoming report. Be ready with the important expectations.

BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the Company will participate in two upcoming investor conferences.

Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2023 Earnings Call Transcript

Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.70 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.75 per share a year ago.

Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.76 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.79 per share a year ago.

Rhythm Pharmaceuticals, Inc. is focused on developing treatments for orphan obesity syndromes caused by defects in the MC4R pathway. Their product Imcivree is currently approved for treating Bardet Biedel syndrome, POMC, PCSK1, and LEPR deficiencies. Q2 2023 revenue more than doubled annually, and Rhythm Pharmaceuticals is conducting late-stage trials in additional orphan obesity indications.